Assessment of the safety, efficacy, tolerability and pharmacokinetics of PegIntron plus Rebetol in pediatric patients with chronic hepatitis C.
Phase of Trial: Phase III
Latest Information Update: 21 Sep 2018
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 04 Feb 2010 Primary endpoint results published in the Journal of Hepatology : 4 Feb 2010
- 20 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.(NCT00104052).
- 20 Oct 2009 Actual initiation date changed from Jul 2007 to Feb 2005 as reported by ClinicalTrials.gov record (NCT00104052).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History